JP2014224134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014224134A5 JP2014224134A5 JP2014154804A JP2014154804A JP2014224134A5 JP 2014224134 A5 JP2014224134 A5 JP 2014224134A5 JP 2014154804 A JP2014154804 A JP 2014154804A JP 2014154804 A JP2014154804 A JP 2014154804A JP 2014224134 A5 JP2014224134 A5 JP 2014224134A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- isolated peptide
- acid sequence
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 2
- 210000004988 splenocyte Anatomy 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 2
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 2
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000011490 co-immunoprecipitation assay Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87362706P | 2006-12-08 | 2006-12-08 | |
| US60/873,627 | 2006-12-08 | ||
| US93003407P | 2007-05-11 | 2007-05-11 | |
| US60/930,034 | 2007-05-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540318A Division JP2010512324A (ja) | 2006-12-08 | 2007-12-07 | ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014224134A JP2014224134A (ja) | 2014-12-04 |
| JP2014224134A5 true JP2014224134A5 (enExample) | 2016-03-24 |
| JP6019457B2 JP6019457B2 (ja) | 2016-11-02 |
Family
ID=39512272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540318A Pending JP2010512324A (ja) | 2006-12-08 | 2007-12-07 | ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 |
| JP2014154804A Active JP6019457B2 (ja) | 2006-12-08 | 2014-07-30 | ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540318A Pending JP2010512324A (ja) | 2006-12-08 | 2007-12-07 | ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8105602B2 (enExample) |
| EP (1) | EP2117571B1 (enExample) |
| JP (2) | JP2010512324A (enExample) |
| CA (1) | CA2671971C (enExample) |
| DK (1) | DK2117571T3 (enExample) |
| ES (1) | ES2636451T3 (enExample) |
| PL (1) | PL2117571T3 (enExample) |
| PT (1) | PT2117571T (enExample) |
| WO (1) | WO2008073312A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005116077A2 (en) * | 2004-05-25 | 2005-12-08 | Attenuon, Llc | LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
| DK2117571T3 (en) | 2006-12-08 | 2017-05-08 | Monopar Therapeutics Inc | Urokinase-type plasminogen activator receptor epitope |
| US8697081B2 (en) * | 2008-04-09 | 2014-04-15 | The Regents Of The University Of Michigan | Method of modulating neovascularization |
| CN102625832A (zh) | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
| TWI488642B (zh) * | 2009-12-09 | 2015-06-21 | Bayer Schering Pharma Ag | 抗－Ｃ４．４ａ抗體及其用途 |
| WO2011100620A2 (en) * | 2010-02-12 | 2011-08-18 | The Regents Of The University Of California | Upar binding agents and methods of use thereof |
| AU2011347327A1 (en) * | 2010-12-22 | 2013-07-18 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | uPAR-antagonists and uses thereof |
| WO2013020898A1 (en) | 2011-08-05 | 2013-02-14 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| DK2812431T3 (da) | 2012-02-09 | 2019-10-14 | Baylor College Medicine | Peptidblandinger til generering af multivirale ctl'er med bred specificitet |
| WO2015004148A1 (en) | 2013-07-08 | 2015-01-15 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof |
| CA2919687A1 (en) * | 2013-08-01 | 2015-02-05 | The General Hospital Corporation | Non-glycosylated supar biomarkers and uses thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CA2998649A1 (en) | 2015-09-18 | 2017-03-23 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| JP7140362B2 (ja) * | 2018-04-09 | 2022-09-21 | 国立大学法人東海国立大学機構 | 活性型組換えアクロシン |
| JP2023532426A (ja) * | 2020-06-15 | 2023-07-28 | モノパー セラピューティクス、インコーポレイテッド | 重症ＣＯＶＩＤ－１９疾患の治療のためのウロキナーゼプラスミノーゲン活性化因子受容体（ｕＰＡＲ）の正確な放射線免疫治療標的化 |
| CA3223227A1 (en) * | 2021-05-21 | 2022-11-24 | NorthStar Medical Technologies, LLC | Urokinase plasminogen activator receptor-targeted radiopharmaceutical |
| CN116410312A (zh) * | 2021-12-29 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型upar单域抗体的开发 |
| CA3245469A1 (en) * | 2022-03-07 | 2023-09-14 | Rush University Medical Center | NEW TREATMENT FOR DIABETES AND KIDNEY DISEASE BY INHIBITION OF THE D2D3 PROTEIN UPAR PROTEOLYTIC |
| CN117264061B (zh) * | 2023-11-22 | 2024-03-01 | 中山大学附属第八医院（深圳福田） | 一种识别uPAR的纳米抗体及其应用 |
| WO2025207781A1 (en) | 2024-03-26 | 2025-10-02 | Monopar Therapeutics Inc. | Antibody radioisotope constructs |
| WO2026019458A1 (en) | 2024-07-19 | 2026-01-22 | Monopar Therpeutics, Inc | Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5057313A (en) * | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8721023D0 (en) | 1987-09-07 | 1987-10-14 | Lepetit Spa | Modified plasminogen activators |
| IT1228881B (it) | 1988-08-12 | 1991-07-09 | Lepetit Spa | Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd |
| US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| US5891664A (en) * | 1989-04-07 | 1999-04-06 | Cancerforskningsfondet Af 1989 | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
| AU652917B2 (en) * | 1989-04-07 | 1994-09-15 | Cancerforskningsfondet Af 1989 | Urokinase-type plasminogen activator receptor |
| US5519120A (en) * | 1989-04-07 | 1996-05-21 | Cancerforskningsfondet Af 1989 | Urokinase-type plasminogen activator receptor antibodies |
| US5443816A (en) * | 1990-08-08 | 1995-08-22 | Rhomed Incorporated | Peptide-metal ion pharmaceutical preparation and method |
| JPH07500486A (ja) | 1990-10-18 | 1995-01-19 | カンサーフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンサーフォースクニング） | ウロキナーゼレセプターに対する抗体とその用途 |
| US5561220A (en) * | 1991-02-08 | 1996-10-01 | Diatech, Inc. | Technetium-99m labeled peptides for imaging inflammation |
| CA2123874A1 (en) | 1991-11-18 | 1993-05-27 | Ikuko F. Mizukami | Methods for detecting and isolating upa-r and inhibiting the binding of upa to upa-r |
| US5556609A (en) * | 1992-02-20 | 1996-09-17 | Rhomed Incorporated | YIGSR peptide radiopharmaceutical applications |
| DE69328092T2 (de) | 1992-05-28 | 2000-07-20 | The University Of Toledo, Toledo | Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial |
| US5608110A (en) * | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
| WO1995004281A1 (en) * | 1993-07-27 | 1995-02-09 | THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION | Quantitative method of measuring cancer cell urokinase and metastatic potential |
| US5532132A (en) * | 1993-09-28 | 1996-07-02 | President And Fellows Of Harvard University | Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor |
| JP2852192B2 (ja) * | 1994-07-08 | 1999-01-27 | カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） | ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体 |
| US5618513A (en) * | 1995-06-07 | 1997-04-08 | Mallinckrodt Medical, Inc. | Method for preparing radiolabeled peptides |
| AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| DE69839060T2 (de) | 1997-11-03 | 2009-01-15 | Human Genome Sciences, Inc. | Vegi, ein inhibitor der angiogenese und des tumorwachstums |
| US6077508A (en) | 1998-03-23 | 2000-06-20 | American Diagnostica Inc. | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
| AU763162B2 (en) | 1999-04-13 | 2003-07-17 | Wilex Ag | Diagnostic and therapeutic use of antibodies against the urokinase receptor |
| ATE361096T1 (de) * | 2001-01-25 | 2007-05-15 | San Raffaele Centro Fond | Antikörper zur modulierung der upa/upar interaktion und deren verwendungen |
| US6846484B2 (en) | 2001-12-28 | 2005-01-25 | Regents Of The University Of Minnesota | DTAT fusion toxin |
| EP2360476B1 (en) | 2002-02-13 | 2017-10-25 | BioMedica Diagnostics Inc. | Methods for selecting treatment regimens and predicting outcomes in cancer patients |
| US20030219837A1 (en) * | 2002-03-18 | 2003-11-27 | Cress Anne E. | Integrin ligand |
| KR100470535B1 (ko) | 2002-06-27 | 2005-02-22 | 재단법인서울대학교산학협력재단 | 유피에이 항체 부착 이뮤노리포좀 |
| WO2004099780A1 (en) | 2003-05-06 | 2004-11-18 | Rigshospitalet | Immunoassays for the detection of urokinase receptor forms |
| AU2004290585A1 (en) | 2003-11-18 | 2005-06-02 | Attenuon Llc | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| US7541159B2 (en) * | 2004-04-14 | 2009-06-02 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Molecular-specific urokinase antibodies |
| WO2005116077A2 (en) | 2004-05-25 | 2005-12-08 | Attenuon, Llc | LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
| EP1851543A2 (en) * | 2005-02-24 | 2007-11-07 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
| DK2117571T3 (en) | 2006-12-08 | 2017-05-08 | Monopar Therapeutics Inc | Urokinase-type plasminogen activator receptor epitope |
-
2007
- 2007-12-07 DK DK07862653.8T patent/DK2117571T3/en active
- 2007-12-07 WO PCT/US2007/025105 patent/WO2008073312A2/en not_active Ceased
- 2007-12-07 PT PT78626538T patent/PT2117571T/pt unknown
- 2007-12-07 ES ES07862653.8T patent/ES2636451T3/es active Active
- 2007-12-07 EP EP07862653.8A patent/EP2117571B1/en active Active
- 2007-12-07 US US12/001,037 patent/US8105602B2/en active Active
- 2007-12-07 CA CA2671971A patent/CA2671971C/en active Active
- 2007-12-07 PL PL07862653T patent/PL2117571T3/pl unknown
- 2007-12-07 JP JP2009540318A patent/JP2010512324A/ja active Pending
-
2014
- 2014-07-30 JP JP2014154804A patent/JP6019457B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014224134A5 (enExample) | ||
| JP2010512324A5 (enExample) | ||
| JP2016026215A5 (enExample) | ||
| JP2017113028A5 (enExample) | ||
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| NZ581418A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| NZ781142A (en) | Anti-vegf protein compositions and methods for producing the same | |
| JP2016104045A5 (enExample) | ||
| RU2014108208A (ru) | Мыши с гуманизированной универсальной легкой цепью | |
| JP2016511750A5 (enExample) | ||
| HK1248714A1 (zh) | Ras蛋白的突变的片段 | |
| JP2015212284A5 (enExample) | ||
| AR085383A1 (es) | Anticuerpos contra el il33r humano y usos de los mismos | |
| JP2016525100A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| MX2016007429A (es) | Mezcla de peptidos. | |
| JP2013530929A5 (enExample) | ||
| PH12016501937A1 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| MX2017005987A (es) | Anticuerpos anti-interleucina(il)-1beta y metodos de uso. | |
| MX340772B (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
| JP2016508503A5 (enExample) | ||
| PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| JP2014525439A5 (enExample) | ||
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| PE20210020A1 (es) | Anticuerpos injertados con peptido natriuretico auricular |